WHO. World malaria report 2014. Geneva: World Health Organization; 2014.
Doolan DL, Doban C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009;22:13–36.
Taylor SM, Parobek CM, Fairhurst RM. Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:457–68.
Lopera-Mesa TM, Doumbia S, Konate D, Anderson JM, Doumbouya M, Keita AS, et al. Impact of red blood cell variants on childhood malaria in Mali: a prospective cohort study. Lancet Haematol. 2015;2:e140–9.
de Mendonca VR, Goncalves MS, Barral-Netto M. The host genetic diversity in malaria infection. J Trop Med. 2012;2012:940616.
Driss A, Hibbert JM, Wilson NO, Iqbal SA, Adamkiewicz TV, Stiles JK. Genetic polymorphisms linked to susceptibility to malaria. Malar J. 2011;10:271.
Mackinnon MJ, Mwangi TW, Snow RW, Marsh K, Williams TN. Heritability of malaria in Africa. PLoS Med. 2005;2:e340.
Gong L, Maiteki-Sebuguzi C, Rosenthal PJ, Hubbard AE, Drakeley CJ, Dorsey G, et al. Evidence for both innate and acquired mechanisms of protection from Plasmodium falciparum in children with sickle cell trait. Blood. 2012;119:3808–14.
Day NP, Hien TT, Schollaardt T. The prognostic and pathophysiologic role of pro- and anti-inflammatory cytokines in severe malaria. J Infect Dis. 1999;180:1288–97.
Dodoo D, Omer FM, Todd J, Akanmori BD, Koram KA, Riley EM. Absolute levels and ratios of pro-inflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J Infect Dis. 2002;185:971–9.
Were T, Hittner JB, Ouma C, Otieno RO, Orago ASS, Ong’echa JM, et al. Suppression of RANTES in children with Plasmodium falciparum malaria. Haematologica. 2006;91:1396–9.
John CC, Opika-Opoka R, Byarugaba J, Idro R, Boivin MJ. Low levels of RANTES are associated with mortality in children with cerebral malaria. J Infect Dis. 2006;194:837–45.
Dietmann A, Helbok R, Lackner P, Issifou S, Lell B, Matsiegui PB, et al. Matrix metalloproteinases and their tissue inhibitors (TIMPs) in Plasmodium falciparum malaria: serum levels of TIMP-1 are associated with disease severity. J Infect Dis. 2008;197:1614–20.
Perera MK, Herath NP, Pathirana SL, Phone-Kyaw M, Alles HK, Mendis KN, et al. Association of high plasma TNF-alpha levels and TNF-alpha/IL-10 ratios with TNF2 allele in severe P. falciparum malaria patients in Sri Lanka. Pathog Glob Health. 2013;107:21–9.
Mahanta A, Kar SK, Kakati S, Baruah S. Heightened inflammation in severe malaria is associated with decreased IL-10 expression levels and neutrophils. Innate Immun. 2015;21:546–52.
Tangteerawatana P, Krudsood S, Kanchanakhan N, Troye-Blomberg M, Khusmith S. Low monocyte to neutrophil ratio in peripheral blood associated with disease complication in primary Plasmodium falciparum infection. Southeast Asian J Trop Med Public Health. 2014;45:517–30.
Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol. 2002;14:129–35.
Majka M, Janowska-Wieczorek A, Ratajczak J, Ehrenman K, Pietrzkowski Z, Kowalska MA, et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood. 2001;97:3075–85.
Ochiel DO, Gordon A, Keller CC, Hittner JB, Kremsner PG, Weinberg JB, et al. Differential regulation of β-chemokines in children with Plasmodium falciparum malaria. Infect Immun. 2005;73:4190–7.
Sarfo BY, Armah HB, Irune I, Adjei AA, Olver CS, Singh S, et al. Plasmodium yoelii 17XL infection upregulates RANTES, CCR1, CCR3, and CCR5 expression, and it induces ultrastructural changes in the cerebellum. Malar J. 2005;4:63.
Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J Exp Med. 2002;195:1145–54.
An P, Nelson GW, Wang L, Donfield S, Goedert JJ, Phair J, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci USA. 2002;99:10002–7.
Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA. 1999;96:4581–5.
Were T, Davenport GC, Yamoa EO, Hittnerd JB, Awandare GA, Otieno MF, et al. Naturally-acquired hemozoin by monocytes promotes suppression of RANTES in children with malarial anemia through an IL-10-dependent mechanism. Microbes Infect. 2009;11:811–9.
McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FM, Ollier WE, Zimmerman PA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicentre AIDS Cohort Study. AIDS. 2000;14:2671–8.
Wichukchinda N, Nakayama EE, Rojanawiwat A, Pathipvanich P, Auwanit W, Vongsheree S, et al. Protective effects of IL4-589T and RANTES -28G on HIV-disease progression in infected Thai females. AIDS. 2006;20:189–96.
Koizumi Y, Kageyama S, Fujiyama Y, Miyashita M, Lwembe R, Ogino K, et al. RANTES -28G delays and DC-SIGN -139C enhances AIDS progression in HIV type 1-infected Japanese hemophiliacs. AIDS Res Hum Retroviruses. 2007;23:713–9.
Gonzalez E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA. 2001;98:5199–204.
Zhao XY, Lee SS, Wong KH, Chan KC, Ma S, Yam WC, et al. Effects of single nucleotide polymorphisms in the RANTES promoter region in healthy and HIV-infected indigenous Chinese. Eur J Immunogenetics. 2004;31:179–83.
Cooke GS, Kerrie T, Ramaley PA, Kaleebu P, Zhuang J, Nakiyingi JS, et al. A polymorphism that reduces RANTES expression is associated with protection from death in HIV-seropositive Ugandans with Advanced disease. J Infect Dis. 2006;194:666–9.
Paxton WA, Neumann AU, Kang S, Deutch L, Brown RC, Koup RA, et al. RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression. J Infect Dis. 2001;183:1678–81.
Virani SS, Nambi V, Hoogeveen R, Wasserman BA, Coresh J, Gonzalez F, et al. Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study. Eur Heart J. 2011;32:459–68.
Liao CH, Yao TC, Chung HT, See LC, Kuo ML, Huang JL. Polymorphisms in the promoter region of RANTES and the regulatory region of monocyte chemo attractant protein-1 among Chinese children with systemic lupus erythematosus. J Rheumatol. 2004;31:2062–7.
Yao TC, Kuo ML, See LC, Chen LC, Yan DC, Ou LS, Shaw CK, Huang JL. The RANTES promoter polymorphism: a genetic risk factor for near-fatal asthma in Chinese children. J Allergy Clin Immunol. 2003;111:1285–92.
Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, Plunkett BS, et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C–C chemokine RANTES. J Immunol. 2000;164:1612–6.
Tanaka KR, Roberts MH, Yamamoto N, Sugiura H, Uehara M, Hopkin JM. Upregulating promoter polymorphisms of RANTES relate to atopic dermatitis. Int J Immunogenet. 2006;33:423–8.
Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Ikeda F, Kanno R, et al. RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. Diabetes Care. 2003;26:892–8.
Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappenberger L, et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J. 2004;25:143846.
Krüger B, Boger CA, Obed A, Farkas S, Hoffmann U, Banas B, et al. RANTES/CCL5 polymorphisms as a risk factor for recurrent acute rejection. Clin Transplant. 2007;21:385–90.
Dossou-Yovo OP, Zaccaria I, Benkerrou M, Hauchecorne M, Alberti C, Rahimy MC, et al. Effects of RANTES and MBL2 gene polymorphisms in sickle cell disease clinical outcomes: association of the g.In1.1T>C RANTES variant with protection against infections. Am J Hematol. 2009;84:378–80.
Ministry of Health. Uganda malaria indicator survey 2009. 2010. p. 1–3.
Okello PE, Van Bortel W, Byaruhanga AM, Correwyn A, Roelants P, Talisuna A, et al. Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg. 2006;75:219–25.
de Onis M, Onyango AW, Borghi E, Garza C, Yang H. WHO Multicentre Growth Reference Study Group: comparison of the World Health Organization Child Growth Standards and the National Center for Health Statistics/WHO international growth reference: implications for child health programmes. Public Health Nutr. 2006;9:942–7.
WHO. Basic malaria microscopy Part I Learner’s guide. 2nd ed. Geneva: World Health Organization; 2010. p. 74–5.
WHO. Communicable diseases cluster: severe falciparum malaria. Trans R Soc Trop Med Hyg. 2009;94(Suppl 1):S1–90.
Bejon P, Berkley JA, Mwangi T, Ogada E, Mwangi I, Maitland K, et al. Defining childhood severe falciparum malaria for intervention studies. PLoS Med. 2007;4:e251.
Hajeer AH, Al Sharif F, Ollier WER. A polymorphism at position −403 in the human RANTES promoter. Eur J Immunogenet. 1999;26:375–6.
Rathore A, Chatterjee A, Sivarama P, Yamamoto N, Singhal PK, Dhole TN. Association of RANTES 403 G/A, 28 C/G and In1.1 T/C Polymorphism With HIV-1 Transmission and Progression Among North Indians. J Med Virol. 2008;80:1133–41.
Parikh S, Dorsey G, Rosenthal PJ. Host polymorphisms and the incidence of malaria in Ugandan children. Am J Trop Med Hyg. 2004;71:750–3.
McClean P. Population and evolutionary genetics. 1998. https://www.ndsu.edu/pubweb/~mcclean/plsc431/popgen/popgen4.htm.
Panda AK, Panda SK, Sahu AN, Tripathy R, Ravindran B, Das BK. Association of ABO blood group with severe falciparum malaria in adults: case control study and meta-analysis. Malar J. 2011;10:309.
Rowe JA, Handel IG, Thera MA, Deans AM, Lyke KE, Kone A, et al. Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci USA. 2007;104:17471–6.